Õppejõud ja üliõpilane: Rollikäsitluse vaade

Üliõpilased ja õppejõud- need on pika ajalooga rollid, mis kõrgkoolide ning ühiskonna kui terviku arengu tõttu on pidevas teisenemises ühelt poolt; teiselt poolt, neis on midagi aegade jooksul olemuslikult muutumatut. Kui üliõpilane alustab oma õpinguid või õppejõud oma tööd, siis peavad nad mõlemad looma kujutluse miks, mida ja kuidas nad teevad ning seejuures arvestama vastandrolli ootusi. Selles protsessis on väga põimuvad indiviidi, organisatsiooni ja ühiskonna tavad ning arusaamad ja seda võib pidada keerukaks, mistõttu pole osapoolte vahelised pinged haruldased. Käesolev uurimus seab eesmärgiks välja selgitada millised on õppejõudude ja üliõpilaste rolliootused ning rollikujutlused, et nende alusel teha ettepanekuid kuidas rollide ebaselgusest tulenevat suhete pingelisust vähendada

Temaatiline riiklik järelevalve õppeasutustes

Järelevalve uuring viidi läbi Eesti õppeasutuste seas selgitamaks välja õppeasutuste juhtide hinnangud ja ettepanekud järelevalvele. Uuringu teostajaks oli OÜ Sinekuur, kes viis läbi analoogse uuringu ka 2004. aastal. Käesolev uuring käsitleb põhjalikult järelevalve erinevaid aspekte. Õppeasutuse juhtkondi tuleb tunnustada aktiivse osalemise ning antud teemal kaasarääkimise ja -mõtlemise eest. Usume, et uuringu tulemused annavad ülevaatliku pildi sellest, millega õppeasutuste juhid on järelevalve teostamisel rahul ning kus oodatakse muudatusi

Üliõpilaste töötamise fenomen Eesti kõrghariduses

Lähtudes Eesti üliõpilaskonnas seas levinud ulatuslikust töötamisest (51% täisajaga õppivatest üliõpilastest töötab viimase üliõpilaste sotsiaal-majandusliku uuringu andmetel täiskoormusega) ning selle otsesest mõjust ning seosest kõrghariduse kvaliteedi ja kõrgharidusele kulutavate ressursside efektiivse kasutamisega, on projekti eesmärgiks saada süvendatud teadmisi täiskoormusega üliõpilaste täiskoormusega töötamise mustrite ja motivatsiooni kohta. Üliõpilaste sügavam töötamise põhjuste analüüs on oluline nii kõrghariduse sisulise kvaliteedi kui ka ressursside otstarbekama kasutamise edendamise aspektist, samuti on oluliseks sisendiks kõrghariduspoliitika tõenduspõhiseks kujundamiseks (paindlikum õpingute ja töötamise ühitamise võimaldamine, kõrghariduse sisulised nõudmised jne)

Warping and F-term uplifting

We analyse the effective supergravity model of a warped compactification with matter on D3 and D7-branes. We find that the main effect of the warp factor is to modify the F-terms while leaving the D-terms invariant. Hence warped models with moduli stabilisation and a small positive cosmological constant resulting from a large warping can only be achieved with an almost vanishing D-term and a F-term uplifting. By studying string-motivated examples with gaugino condensation on magnetised D7-branes, we find that even with a vanishing D-term, it is difficult to achieve a Minkowski minimum for reasonable parameter choices. When coupled to an ISS sector the AdS vacua is uplifted, resulting in a small gravitino mass for a warp factor of order 10^-5.Comment: 24 pages, v3: typos, minor clarifications adde

Eesti teadus- ja arendusasutuste juhtimismustrid

Teadus- ja arendusasutuste juhtimis- ja majandamismudelidAntud uuringu eesmärgiks on esitada ülevaade ülikoolide juhtimismustritest, juhtimise võimalustest ning väljakutsetest teaduskirjanduse ja empiiriliste uuringute põhjal. Juhtimismustrite uurimise initsieeris Tartu Ülikool ning seetõttu kajastab nii probleemide fookus kui ka empiiriline materjal valdavalt Tartu Ülikooli ja selle allüksuste juhtimist, kuid võimalusel on võrdluseks kaasatud ka teisi Eestis tegutsevaid ülikoole. Raporti esimeses peatükis keskendutakse strateegia formuleerimise etapil lahendamist vajavatele küsimustele ning teises vaadeldakse konkreetsemaid juhtimisteemasid, mis tulenevad strateegia elluviimisest operatiivsel tasandil. Seejuures on lähtutud üldiselt- üksikule lähenemist ning alapeatükk 2.4 integreerib nii organisatsiooni, meeskonna kui ka indiviidi tasandid.http://tips.ut.ee/index.php?module=32&op=1&id=364

Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis

<p>Abstract</p> <p>Background</p> <p>The chemokine receptor CCR5 has been detected at elevated levels on synovial T cells, and a 32 bp deletion in the <it>CCR5 </it>gene leads to a non-functional receptor. A negative association between the <it>CCR5Δ32 </it>and rheumatoid arthritis (RA) has been reported, although with conflicting results. In juvenile idiopathic arthritis (JIA), an association with CCR5 was recently reported. The purpose of this study was to investigate if the <it>CCR5Δ32 </it>polymorphism is associated with RA or JIA in Norwegian cohorts.</p> <p>Methods</p> <p>853 RA patients, 524 JIA patients and 658 controls were genotyped for the <it>CCR5Δ32 </it>polymorphism.</p> <p>Results</p> <p>The <it>CCR5Δ32 </it>allele frequency was 11.5% in the controls vs. 10.4% in RA patients (OR = 0.90; <it>P </it>= 0.36) and 9.7% in JIA patients (OR = 0.85; <it>P </it>= 0.20). No decreased homozygosity was observed for <it>CCR5Δ32</it>, as previously suggested.</p> <p>Conclusion</p> <p>Our data do not support an association between the <it>CCR5Δ32 </it>allele and Norwegian RA or JIA patients. Combining our results with those from a recently published meta-analysis still provide evidence for a role for <it>CCR5Δ32 </it>in RA, albeit substantially weaker than the effect first reported.</p

Concurrent Oral 1 - Rheumatoid Arthritis: Treatment [OP4-OP9]: OP4. Inhibition of Radiographic Progression and Improvements in Physical Function at 2 Years, with Increasing Clinical Efficacy Over Time, in Rheumatoid Arthritis (Ra) Patients Treated with Tocilizumab (Tcz): The Lithe Study

Background: Patients with moderate to severe RA who remained on methotrexate (MTX) despite inadequate response were treated with TCZ in a double-blind, randomized, controlled phase 3 trial. Results of a 2-year planned analysis from this study are presented. Methods: Patients were randomized to treatment with TCZ 4 mg/kg + MTX (TCZ4), TCZ 8 mg/kg + MTX (TCZ8) or placebo + MTX (CON) every 4 weeks. If patients failed to respond ( 60% of patients and the DAS28 remission (DAS28 < 2.6) rate was 48% at week 52 and continued to increase to week 104. By week 52, patients treated with TCZ8 had clinically significant improvements in SJC that were maintained through week 104. Rates per 100 PY for adverse events (AEs) were higher in TCZ8 and TCZ4 (263.6, 275.4) vs CON patients (251.4) while rates for serious AEs were comparable (11.4, 12.1, 10.9, respectively). Rates per 100 PY of AEs leading to withdrawal (7.4, 32.5, 4.8) and treatment modification (8.4, 30.7, 20.4) were higher in TCZ8 and TCZ4 vs CON patients, respectively and death rates were comparable (0.6, 0.2, 0.4). Conclusions: Treatment with TCZ + MTX inhibits radiographic progression over 2 years and improves physical function as shown by DAS28 remission, LDAS and low SJC, with a manageable safety profile. Disclosure statement: E.A., F. Hoffmann-La Roche - Employee. P.A., F. Hoffmann-La Roche - Employee. R.B.-V., F. Hoffmann-La Roche - Honoraria. R.F., Genentech - Research Funding, Honoraria. J.K., F. Hoffmann-La Roche - Research funding, Honorari

Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.

INTRODUCTION: We have hypothesized that incompatibility between the G1m genotype of the patient and the G1m1 and G1m17 allotypes carried by infliximab (INX) and adalimumab (ADM) could decrease the efficacy of these anti-tumor necrosis factor (anti-TNF) antibodies in the treatment of rheumatoid arthritis (RA). METHODS: The G1m genotypes were analyzed in three collections of patients with RA totaling 1037 subjects. The first, used for discovery, comprised 215 Spanish patients. The second and third were successively used for replication. They included 429 British and Greek patients and 393 Spanish and British patients, respectively. Two outcomes were considered: change in the Disease Activity Score in 28 joint (ΔDAS28) and the European League Against Rheumatism (EULAR) response criteria. RESULTS: An association between less response to INX and incompatibility of the G1m1,17 allotype was found in the discovery collection at 6 months of treatment (P = 0.03). This association was confirmed in the replications (P = 0.02 and 0.08, respectively) leading to a global association (P = 0.001) that involved a mean difference in ΔDAS28 of 0.4 units between compatible and incompatible patients (2.3 ± 1.5 in compatible patients vs. 1.9 ± 1.5 in incompatible patients) and an increase in responders and decrease in non-responders according to the EULAR criteria (P = 0.03). A similar association was suggested for patients treated with ADM in the discovery collection, but it was not supported by replication. CONCLUSIONS: Our results suggest that G1m1,17 allotypes are associated with response to INX and could aid improved therapeutic targeting in RA

Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach

Background: This analysis assessed, on a group level, whether there is a long-term advantage for early RA patients treated with adalimumab (ADA) + MTX vs those initially treated with placebo (PBO) + MTX who either responded to therapy or added ADA following inadequate response (IR). Methods: OPTIMA was a 78- week, randomized, controlled trial of ADA + MTX vs PBO + MTX in MTX-naïve early (<1 year) RA patients. Therapy was adjusted at week 26: ADA + MTX-responders (R) who achieved DAS28 (CRP) <3.2 at weeks 22 and 26 (Period 1, P1) were re-randomized to withdraw or continue ADA and PBO + MTX-R continued randomized therapy for 52 weeks (P2); IR-patients received open-label (OL) ADA + MTX during P2. This post hoc analysis evaluated the proportion of patients at week 78 with DAS28 (CRP) <3.2, HAQ-DI <0.5, and/or ΔmTSS ≤0.5 by initial treatment. To account for patients who withdrew ADA during P2, an equivalent proportion of R was imputed from ADA + MTX-R patients. Results: At week 26, significantly more patients had low disease activity, normal function, and/or no radiographic progression with ADA + MTX vs PBO + MTX (Table 1). Differences in clinical and functional outcomes disappeared following additional treatment, when PBO + MTX-IR (n = 348/460) switched to OL ADA + MTX. Addition of OL ADA slowed radiographic progression, but more patients who received ADA + MTX from baseline had no radiographic progression at week 78 than patients who received initial PBO + MTX. Conclusions: Early RA patients treated with PBO + MTX achieved comparable long-term clinical and functional outcomes on a group level as those who began ADA + MTX, but only when therapy was optimized by the addition of ADA in PBO + MTX-IR. Still, ADA + MTX therapy conferred a radiographic benefit although the difference did not appear to translate to an additional functional benefit. Disclosures: P.E., AbbVie, Merck, Pfizer, UCB, Roche, BMS—Provided Expert Advice, Undertaken Trials, AbbVie—AbbVie sponsored the study, contributed to its design, and participated in the collection, analysis, and interpretation of the data, and in the writing, reviewing, and approval of the final version. R.F., AbbVie, Pfizer, Merck, Roche, UCB, Celgene, Amgen, AstraZeneca, BMS, Janssen, Lilly, Novartis—Research Grants, Consultation Fees. S.F., AbbVie—Employee, Stocks. A.K., AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, UCB—Research Grants, Consultation Fees. H.K., AbbVie—Employee, Stocks. S.R., AbbVie—Employee, Stocks. J.S., AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, GlaxoSmithKline, Lilly, Pfizer (Wyeth), MSD (Schering-Plough), Novo-Nordisk, Roche, Sandoz, UCB—Research Grants, Consultation Fees. R.V., AbbVie, BMS, GlaxoSmithKline, Human Genome Sciences, Merck, Pfizer, Roche, UCB Pharma—Consultation Fees, Research Support. Table 1.Week 78 clinical, functional, and radiographic outcomes in patients who received continued ADA + MTX vs those who continued PBO + MTX or added open-label ADA following an inadequate response ADA + MTX, n/N (%)a PBO + MTX, n/N (%)b Outcome Week 26 Week 52 Week 78 Week 26 Week 52 Week 78 DAS28 (CRP) <3.2 246/466 (53) 304/465 (65) 303/465 (65) 139/460 (30)*** 284/460 (62) 300/460 (65) HAQ-DI <0.5 211/466 (45) 220/466 (47) 224/466 (48) 150/460 (33)*** 203/460 (44) 208/460 (45) ΔmTSS ≤0.5 402/462 (87) 379/445 (86) 382/443 (86) 330/459 (72)*** 318/440 (72)*** 318/440 (72)*** DAS28 (CRP) <3.2 + ΔmTSS ≤0.5 216/462 (47) 260/443 (59) 266/443 (60) 112/459 (24)*** 196/440 (45) 211/440 (48)*** DAS28 (CRP) <3.2 + HAQ-DI <0.5 + ΔmTSS ≤0.5 146/462 (32) 168/443 (38) 174/443 (39) 82/459 (18)*** 120/440 (27)*** 135/440 (31)** aIncludes patients from the ADA Continuation (n = 105) and OL ADA Carry On (n = 259) arms, as well as the proportional equivalent number of responders from the ADA Withdrawal arm (n = 102). bIncludes patients from the MTX Continuation (n = 112) and Rescue ADA (n = 348) arms. Last observation carried forward: DAS28 (CRP) and HAQ-DI; Multiple imputations: ΔmTSS. ***P < 0.001 and **iP < 0.01, respectively, for differences between initial treatments from chi-squar